| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biochemistry and Biophysics |
Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan 48201 [R. M., H. B., S. S.], and Division of Cancer Genetics, Dana-Farber Cancer Institute, Boston, Massachusetts 02115 [R. S.]
Maspin is a novel serine protease inhibitor (serpin) with tumor suppressive potential in breast and prostate cancer, acting at the level of tumor invasion and metastasis. It was subsequently demonstrated that maspin inhibits tumor invasion, at least in part, by inhibiting cell motility. Interestingly, in cell-free solutions, maspin does not inhibit several serine proteases including tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA). Despite the recent biochemical evidence that maspin specifically inhibits tissue-type plasminogen activator that is associated with fibrinogen or poly-L-lysine, the molecular mechanism underlying the tumor-suppressive effect of maspin remains elusive. The goal of this study was to investigate the effect of maspin on cell surface-associated uPA. In our experimental system, we chose prostate carcinoma DU145 cells because these cells mediate plasminogen activation primarily by uPA, as shown by two different colorimetric enzyme activity assays. Purified recombinant maspin produced in baculovirus-infected Spodoptera frugiperda Sf9 insect cells [rMaspin(i)] binds specifically to the surface of DU145 cells, inhibits the DU145 cell surface-bound uPA, and forms a stable complex with the uPA in DU145 cell lysate. The inhibitory effect of rMaspin(i) on cell surface-bound uPA was similar to that of an uPA-neutralizing antibody and was reversed by a polyclonal antibody against the reactive site loop sequence of maspin. The Ki value for rMaspin(i) in cell surface-mediated plasminogen activation was 20 nM, which was comparable to the Ki values for plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2, respectively. Furthermore, the proteolytic inhibitory effect of rMaspin(i) was quantitatively consistent with its inhibitory effect on the motility of DU145 cells in vitro. Our data demonstrate an important role for the prostate carcinoma cell surface in mediating the inhibitory interaction between rMaspin(i) and uPA. Thus, future maspin-based therapeutic strategies may prove useful in blocking the invasion and metastasis of uPA-positive prostate carcinoma.
This article has been cited by other articles:
|
|
 |
|
  L.-j. Shao, H. Y. Shi, G. Ayala, D. Rowley, and M. Zhang Haploinsufficiency of the Maspin Tumor Suppressor Gene Leads to Hyperplastic Lesions in Prostate Cancer Res., July 1, 2008; 68(13): 5143 - 5151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Al-Ayyoubi, B. S. Schwartz, and P. G. W. Gettins Maspin Binds to Urokinase-type and Tissue-type Plasminogen Activator through Exosite-Exosite Interactions J. Biol. Chem., July 6, 2007; 282(27): 19502 - 19509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Chu, J. Cheng, J. S. Foley, B. H. Mecham, C. A. Owen, K. J. Haley, T. J. Mariani, I. S. Kohane, D. J. Tschumperlin, and J. M. Drazen Induction of the Plasminogen Activator System by Mechanical Stimulation of Human Bronchial Epithelial Cells Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 628 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tekin, M. B. Padua, A. M. Brad, M. L. Rhodes, and P. J. Hansen Expression and Properties of Recombinant Ovine Uterine Serpin Experimental Biology and Medicine, September 1, 2006; 231(8): 1313 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Cella, A. Contreras, K. Latha, J. M. Rosen, and M. Zhang Maspin is physically associated with {beta}1 integrin regulating cell adhesion in mammary epithelial cells FASEB J, July 1, 2006; 20(9): 1510 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yin, J. Lockett, Y. Meng, H. Biliran Jr., G. E. Blouse, X. Li, N. Reddy, Z. Zhao, X. Lin, J. Anagli, et al. Maspin Retards Cell Detachment via a Novel Interaction with the Urokinase-Type Plasminogen Activator/Urokinase-Type Plasminogen Activator Receptor System. Cancer Res., April 15, 2006; 66(8): 4173 - 4181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Shellenberger, A. Mazumdar, Y. Henderson, K. Briggs, M. Wang, C. Chattopadhyay, A. Jayakumar, M. Frederick, and G. L. Clayman Headpin: A Serpin with Endogenous and Exogenous Suppression of Angiogenesis Cancer Res., December 15, 2005; 65(24): 11501 - 11509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yin, X. Li, Y. Meng, R. L. Finley Jr., W. Sakr, H. Yang, N. Reddy, and S. Sheng Tumor-suppressive Maspin Regulates Cell Response to Oxidative Stress by Direct Interaction with Glutathione S-Transferase J. Biol. Chem., October 14, 2005; 280(41): 34985 - 34996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, S. Yin, N. Reddy, C. Spencer, and S. Sheng Bax Mediates the Apoptosis-Sensitizing Effect of Maspin Cancer Res., March 1, 2004; 64(5): 1703 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Akiyama, C. Maesawa, S. Ogasawara, M. Terashima, and T. Masuda Cell-Type-Specific Repression of the Maspin Gene Is Disrupted Frequently by Demethylation at the Promoter Region in Gastric Intestinal Metaplasia and Cancer Cells Am. J. Pathol., November 1, 2003; 163(5): 1911 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Feldman, V. I. Sementchenko, M. Gayed, M. M. Fraig, and D. K. Watson Pdef Expression in Human Breast Cancer Is Correlated with Invasive Potential and Altered Gene Expression Cancer Res., August 1, 2003; 63(15): 4626 - 4631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Cher, H. R. Biliran Jr., S. Bhagat, Y. Meng, M. Che, J. Lockett, J. Abrams, R. Fridman, M. Zachareas, and S. Sheng Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis PNAS, June 24, 2003; 100(13): 7847 - 7852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bass, A.-M. M. Fernandez, and V. Ellis Maspin Inhibits Cell Migration in the Absence of Protease Inhibitory Activity J. Biol. Chem., November 27, 2002; 277(49): 46845 - 46848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Biliran Jr. and S. Sheng Pleiotrophic Inhibition of Pericellular Urokinase-type Plasminogen Activator System by Endogenous Tumor Suppressive Maspin Cancer Res., December 1, 2001; 61(24): 8676 - 8682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Helenius, O. R. Saramaki, M. J. Linja, T. L. J. Tammela, and T. Visakorpi Amplification of Urokinase Gene in Prostate Cancer Cancer Res., July 1, 2001; 61(14): 5340 - 5344. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
